The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

As a numerical comparison, Keytruda monotherapy achieved a 45% ORR in first-line PD-L1 high patients ... drug conjugates and bispecific antibodies. "ESMO 2024: TIGIT race tightens with first ...

Having said that, it is because this company made a move about a month ago to receive ex-China development and commercial rights to ImmuneOnco's PD-L1/VEGF bispecific antibody known as IMM2510 ...

金融界 2024 年 9 月 3 日消息，天眼查知识产权信息显示，原启生物科技（上海）有限责任公司申请一项名为“抗TIGIT 和 PD-L1 的双特异性抗原结合蛋白及其用途“，公开号 CN202380018211.5，申请日期为 2023 年 1 月。 专利摘要显示，本申请涉及一种分离的抗原结合蛋白 ...

NEW YORK – Akeso Biopharma's bispecific antibody ivonescimab (AK112), which targets both PD-1 and VEGF, bested Merck's anti-PD-1 drug Keytruda (pembrolizumab) as a frontline treatment for patients ...

Novartis, meanwhile, handed rights to TIGIT antibody ociperlimab to BeiGene a year ago, two years after paying $300 million upfront for an option on the drug. Like PD-1/PD-L1, TIGIT is thought to ...

The rate is also almost double the discontinuation rates reported for Roche's TIGIT/PD-L1 combo of tiragolumab and Tecentriq in the same setting, Leerink Partners said. To cut down on unnecessary ...